Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 7/20 | 0.38 |
| ▸ | VHL | P40337 | 1/20 | 0.37 |
| ▸ | ELOC | Q15369 | 1/20 | 0.37 |
| ▸ | ELOB | Q15370 | 1/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2046737 | 1.00 | ELANE (0.38) | ELANEVHLELOCELOBACE | |
| SCHEMBL2052878 | 0.94 | ELANE (0.37) | ELANEVHLELOCELOBNR1I2 | |
| SCHEMBL2052881 | 0.94 | ELANE (0.37) | ELANEVHLELOCELOBNR1I2 | |
| SCHEMBL2052879 | 0.94 | ELANE (0.37) | ELANEVHLELOCELOBNR1I2 | |
| SCHEMBL1434005 | 0.88 | ELANE (0.41) | ELANEVHLELOCELOBACE | |
| SCHEMBL1434008 | 0.88 | ELANE (0.41) | ELANEVHLELOCELOBACE | |
| SCHEMBL1433869 | 0.87 | ELANE (0.38) | ELANEVHLELOCELOBACE | |
| SCHEMBL1433868 | 0.87 | ELANE (0.38) | ELANEVHLELOCELOBACE | |
| SCHEMBL12646096 | 0.87 | ELANE (0.38) | ELANEVHLELOCELOBACE | |
| SCHEMBL1433778 | 0.86 | ELANE (0.42) | ELANEVHLELOCELOBACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300490-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2015-03-04 | — | — | EP | disclosed |
| EP-2365980-B1 | HCV inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2013-04-17 | — | — | EP | disclosed |
| US-8283310-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283310-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283310-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-09 | — | — | US | disclosed |
| EP-2365980-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-09-21 | — | — | EP | disclosed |
| US-7964560-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964560-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964560-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-06-21 | — | — | US | disclosed |
| WO-2010077783-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100150866-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-17 | — | — | US | disclosed |
| US-20100150866-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-17 | — | — | US | disclosed |
| US-20100150866-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-17 | — | — | US | disclosed |
| US-20090304626-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-10 | — | — | US | disclosed |
| US-20090304626-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-10 | — | — | US | disclosed |
| US-20090304626-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090304626-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | ELANE 1285/4885VHL 3152/4885ELOC 810/4885 |
| US-20100150866-A1 | Hepatitis C Virus Inhibitors | HAVCR2, HCCS, PYGL | ELANE 1285/4885VHL 3152/4885ELOC 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.